Health-Related Quality of Life Impact from Adding Bevacizumab to Cisplatin-Pemetrexed in Malignant Pleural Mesothelioma in the MAPS IFCT-GFPC-0701 Phase III Trial.

  • Etude concernée: MAPS
  • Auteurs / Authors: Eberst G, Anota A, Scherpereel A, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, Molinier O, Léna H, Rivière F, Monnet I, Gounant, V, Janicot H, Gervais R, Locher C, Charton E, Morin F, Zalcman G, Westeel V
  • Journal / Conference: Clinical Cancer Research
  • Année / Year: 2019
  • PMID: 31175096
  • Lien vers la publication: https://pubmed.ncbi.nlm.nih.gov/31175096/